Board of Directors
Candice Aaron is currently the Chief Compliance Officer for GE Capital Equipment and Commercial Distribution Finance, working out of GE’s Dallas office. In 2009, she left her law firm partnership, where she led the firm’s corporate governance and litigation practice, to join GE Capital. Aaron graduated from the University of Michigan and the University of Pennsylvania Law School.
She has been involved with LIVESTRONG since 2008 when she was the founding Vice Chairperson of the LIVESTRONG Young Leader’s Council. In addition, along with her husband, Brent, Aaron is a member of the LIVESTRONG President’s Circle. An eight-year cancer survivor, Aaron has served on the LIVESTRONG Board of Directors since 2012 and became Chairman of the Board in 2016.
Joseph C. Aragona
Joe Aragona is a founder and General Partner of Austin Ventures. AV has over $3 billion under management and is the most active venture and growth equity firm in Texas and among the most established in the nation. Since joining AV in 1982, Joe has focused on information technology and growth equity investing and has worked with software, communications, semiconductor and service companies. Prior to joining Austin Ventures, Joe earned both his MBA and bachelor's degree from Harvard University and worked in the Merchant Banking Group of the Bank of Boston and Chemical Bank
Joe was a member of the Board of Directors of the National Venture Capital Association (NVCA) from 1999 - 2006, chaired its Research Committee, and served as Chairman of the Board. Joe is also a member of the Board of Directors of Casa Montessori, an early childhood development center.
Julian C. Day was elected chairman and chief executive officer of RadioShack Corporation on July 6, 2006 by the company's board of directors. Day has successfully served in senior leadership positions at several large publicly traded companies and has earned a reputation for successfully turning around companies that have experienced slow growth.
Day's retailing experience includes leadership positions at Kmart Holding Corporation (formerly the parent company of Kmart Corporation), where he was elected as president and chief operating officer in March 2002 and was promoted to chief executive officer in 2003. Day successfully took the company out of bankruptcy and led the company to substantially exceed its profit plans. Under his leadership, the company's value increased from $1.5 billion to $9 billion.
Prior to joining Kmart, he spent two years at Sears, first as chief financial officer and then as chief operating officer. As COO, he was a member of the Office of the Chief Executive and oversaw finance, logistics/supply chain, store operations, information technology and the company's business-to-business partnerships.
Before joining Sears, Day served as executive vice president and chief financial officer for Safeway, Inc., where he was responsible for financial, technology and real estate operations. While at Safeway, he strengthened the balance sheet and improved the company's credit rating, increased return on capital expenditures while tripling annual spending levels, and re-engineered the real estate development and construction process.
Day holds undergraduate and master's degrees from Oxford University and an MBA from the London Business School.
Jeffery C. Garvey
Jeff Garvey is the founding chairman and currently serves on the Executive Committee of the Board of Directors of the LIVESTRONG Foundation. Jeff is a pioneering venture capitalist, nationally recognized philanthropist and active contributor in the Austin community.
Jeff is the co-founder of Austin Ventures, one of the largest and most active venture capital firms in the U.S. From 1979-1999, he served as the firm’s first investment professional and a general partner and leader of the company through its first six investment funds. Previously, from 1971-1979, Jeff held several senior lending and management positions at PNC Bank, in both Philadelphia and Pittsburgh.
The organizations in which Jeff has served as board member, adviser or donor over the years include KLRU Public Television, The Center For Childhood Protection, The First Tee of Greater Austin, Helping Hand Home, Children’s Medical Center Foundation, Ronald McDonald House Charities, Settlement Home for Children, The Association for Professional Fundraisers, Gladney Home For Adoption, West Austin Youth Association, St. Andrews Episcopal School, Deerfield Academy and St. Edward’s University.
David Johnson, M.D.
Dr. Johnson is the Donald W. Seldin Distinguished Chair in Internal Medicine and Chairman of the Department of Internal Medicine at UT Southwestern Medical Center in Dallas, Texas. He is a member of the ABIM Board of Directors and serves as the Chair of the ABIM Subspecialty Board for Medical Oncology. From 1983 until 2010 Dr. Johnson was a member of the faculty at the Vanderbilt University Medical School where he held the Cornelius A. Craig Chair of Medical & Surgical Oncology and served as the Director of the Division of Hematology and Medical Oncology and Deputy Director of the Vanderbilt-Ingram Cancer Center.
Dr. Johnson's research interests involve the study of the biology of lung cancer and improving the treatment of this and other solid tumors. He played a key role in the development of the new targeted drugs bevacizumab (Avastin®) and erlotinib (Tarceva®) both of which are now FDA-approved for the treatment of lung cancer. He has authored over 330 peer reviewed articles, 40 book chapters and edited four oncology textbooks. In 2004-2005, Dr. Johnson served as President of the American Society of Clinical Oncology (ASCO) during which time he helped advance ASCO's quality of care activity known as the Quality Oncology Practice Initiative (or QOPI®). QOPI® was subsequently adopted as a Practice Improvement Module for diplomates seeking to maintain their certification in medical oncology. He was instrumental in establishing ASCO's Cancer Survivorship Program. Dr. Johnson also has served on the Food and Drug Administration's Oncology Drug Advisory Committee, as chairman of the Thoracic Committee of the Eastern Cooperative Oncology Group and on the Board of Directors of the National Comprehensive Cancer Network (NCCN), the International Association for the Study of Lung Cancer (IASLC) and the LIVESTRONG Foundation.
Dr. Johnson earned his medical degree from the Medical College of Georgia and obtained his medical oncology training at Vanderbilt University. He is board certified in internal medicine and medical oncology.
Amelie G. Ramirez, Dr. P.H.
Amelie G. Ramirez, DrPH, is a Professor of Epidemiology and Biostatistics at The University of Texas Health Science Center at San Antonio, where she also is founding director of the Institute for Health Promotion Research (IHPR). She also is the Dielmann Chair in Health Disparities Research and Community Outreach and the Max and Minnie Tomerlin Voelcker Endowed Chair in Cancer Healthcare Disparities and Outreach at the Cancer Therapy & Research Center (CTRC) at The University of Texas Health Science Center at San Antonio. She also is Co-Associate Director of the Cancer Prevention and Population Science program at the CTRC.
Over the past 25 years, Dr. Ramirez has directed many research programs focused on human and organizational communication to reduce chronic disease and cancer health disparities affecting Hispanics/Latinos and other populations. In 2007, Dr. Ramirez was elected to the Institute of Medicine of the National Academies and was named a Professor of Survivorship by Susan G. Komen For the Cure. She chairs the CDC's Breast and Cervical Cancer Early Detection and Control Advisory Committee and Komen's National Hispanic/Latino Advisory Council, and is a member of Komen's Scientific Advisory Board, Avon Foundation Breast Cancer Crusade Scientific Advisory Board, the LIVESTRONG Foundation's Board of Directors and the Institute of Medicine Roundtable on Translating Genomic Based Research for Health.
Mr. Jeremiah Robins is Chairman & CEO of Great Pond Management Company, LLC – a US based Private Equity firm specializing in the acquisition of controlling positions in, and the redevelopment of, underperforming middle market manufacturing companies. Founded in 1979, GPMC has successfully invested across a broad industrial spectrum including enterprises in the Brass, Iron, Steel, Specialty Chemical, HVAC, Semiconductor Packaging, Coated and Specialty Optics and Medical Device markets. Mr. Robins & GPMC began operating in mainland China in early 1990 and the firm has had a continuing presence in the PRC since that time. At present, GPMC maintains a spectrum of investments each with their own very significant presence in China. These include Rotation Dynamics Corporation, a manufacturer of specialty materials for industrial applications, China Centric Associates, a consultancy specializing in US-China transactions, and PharmaLegacy, a provider of in-vivo laboratory services for the Pharmaceutical industry. A US citizen, Mr. Robins divides his time equally between the USA and China and maintains a home and office in each country.
Blaine P. Rollins
Blaine Rollins is a testicular cancer survivor since 1998. He is managing director, senior portfolio manager and member of the Investment Committee at 361 Capital and is responsible for manager due-diligence, investment research, portfolio construction, hedging and trading strategies.
Prior to joining 361 Capital, Mr. Rollins was an independent investor from July 2006 to February 2011. Previously, he served as Executive Vice President at Janus Capital Corporation and portfolio manager of the Janus Fund, Janus Balanced Fund, Janus Equity Income Fund, Janus Aspen Growth Portfolio, Janus Advisor Large Cap Growth Fund, and the Janus Triton Fund. He began his career as a financial analyst at AMG Guaranty Trust (formerly Asset Management Group).
A frequent industry speaker, Mr. Rollins earned a Bachelor’s degree in Finance from the University of Colorado, and he is a Chartered Financial Analyst.
Lawrence Shulman, M.D.
Lawrence N. Shulman, M.D., is Chief of Staff, Senior Vice-President for Medical Affairs, and Chief, Division of General Oncology, Department of Medical Oncology at Dana-Farber Cancer Institute (DFCI). He is a specialist in the treatment of breast cancer and focuses on the development of new therapies for these patients.
Dr. Shulman has served as one of the component leaders through the DFCI strategic planning initiative. He is Director of the Department of Regional Strategy and Development, and oversees DFCI ambulatory oncology units at several regional sites in the Northeast. He is also physician leader for the development of clinical information systems for DFCI.
He is a member of the Commission on Cancer of the American College of Surgeons, and Chair of their Quality Integration Committee. He is the former Chair of the American Society of Clinical Oncology's (ASCO) Quality of Care Committee and a former member of ASCO's Health Information Technology Workgroup.
Shulman is the Director for the Center for Global Cancer Medicine at DFCI, and works closely with Partners In Health, where he is Senior Advisor in Oncology and a member of their Board, helping to lead the development of structured cancer programs for their resource-limited healthcare sites in Rwanda, Malawi and Haiti. He is a member of ASCO’s Global Oncology Leadership Task Force. Shulman is also the Co-Chair of a Taskforce to re-define the World Health Organization’s Essential Medicines List for Cancer.
Cindy L. Sweeting, CFA
Cindy Sweeting is the president of Templeton Investment Counsel, LLC and the director of portfolio management for the Templeton Global Equity Group (TGEG) for Franklin Templeton Investments. Sweeting has lead portfolio manager responsibility for the TIF-Foreign Equity Series and portfolio management responsibility for institutional separate account relationships. She also oversees the institutional segment of TGEG's global investment management business.
Sweeting previously served as TGEG's director of research, president of Templeton Global Advisors Limited and lead portfolio manager for Templeton Growth Fund and Templeton Growth (Euro) Fund. Prior to joining Templeton in 1997, Sweeting was the senior vice president of investments with McDermott International Investments. She entered the financial services industry in 1983.
Sweeting holds a B.S. in business administration with a concentration in finance, summa cum laude, from Georgetown University. She is a Chartered Financial Analyst (CFA) Charterholder.